PET/MRI and Novel Targets for Breast Cancer

Hyun Woo Chung,Kyoung Sik Park,Ilhan Lim,Woo Chul Noh,Young Bum Yoo,Sang Eun Nam,Young So,Eun Jeong Lee
DOI: https://doi.org/10.3390/biomedicines12010172
IF: 4.757
2024-01-13
Biomedicines
Abstract:Breast cancer, with its global prevalence and impact on women's health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucial roles in local-regional assessment, while bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) aid in evaluating distant metastasis. Despite the proven utility of 18F-FDG PET/CT in various cancers, its limitations in breast cancer, such as high false-negative rates for small and low-grade tumors, have driven exploration into novel targets for PET radiotracers, including estrogen receptor, human epidermal growth factor receptor-2, fibroblast activation protein, and hypoxia. The advent of PET/MRI, which combines metabolic PET information with high anatomical detail from MRI, has emerged as a promising tool for breast cancer diagnosis, staging, treatment response assessment, and restaging. Technical advancements including the integration of PET and MRI, considerations in patient preparation, and optimized imaging protocols contribute to the success of dedicated breast and whole-body PET/MRI. This comprehensive review offers the current technical aspects and clinical applications of PET/MRI for breast cancer. Additionally, novel targets in breast cancer for PET radiotracers beyond glucose metabolism are explored.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The paper primarily explores the application of Positron Emission Tomography and Magnetic Resonance Imaging fusion technology (PET/MRI) in the diagnosis, staging, treatment response evaluation, and follow-up of breast cancer, and investigates new targets beyond glucose metabolism. ### Problems the paper aims to address: 1. **Improving early detection and accurate staging of breast cancer**: As one of the most common cancers among women worldwide, effective early detection and accurate staging of breast cancer are crucial for patient treatment outcomes. Traditional imaging methods such as mammography, ultrasound, and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) play important roles in local area assessment, but bone scintigraphy and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) have limitations in evaluating distant metastasis, especially with high false-negative rates for small or low-grade tumors. 2. **Exploring new PET tracer targets**: To overcome the limitations of 18F-FDG PET/CT in breast cancer, researchers have begun exploring new PET tracer targets, including estrogen receptor (ER), human epidermal growth factor receptor-2 (HER2), fibroblast activation protein (FAP), and hypoxia. These new targets help improve the diagnosis and management of breast cancer. 3. **Technical advancements and clinical applications of PET/MRI**: PET/MRI, which combines PET metabolic information with MRI's high anatomical detail, has been proposed as a promising imaging tool for breast cancer. The article details the technical advancements in the integration of PET/MRI systems, patient preparation, and optimized imaging protocols, and discusses specific application cases in breast cancer diagnosis, initial staging, treatment response evaluation, and follow-up. Through the above research, the paper aims to comprehensively showcase the latest advancements and potential advantages of PET/MRI technology in breast cancer diagnosis and treatment, providing more possibilities for precision medicine in the future.